Actuate Therapeutics Inc (ACTU)
Actuate Therapeutics Inc Statistics
Share Statistics
Actuate Therapeutics Inc has 19.53M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 19.53M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 125 |
| FTD / Avg. Volume | 0.39% |
Short Selling Information
The latest short interest is -, so null% of the outstanding shares have been sold short.
| Short Interest | - |
| Short % of Shares Out | null% |
| Short % of Float | null% |
| Short Ratio (days to cover) | null |
Valuation Ratios
The PE ratio is -2.44 and the forward PE ratio is null. Actuate Therapeutics Inc's PEG ratio is -0.03.
| PE Ratio | -2.44 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | 1.5 |
| PB Ratio | 639.69 |
| P/FCF Ratio | -3.05 |
| PEG Ratio | -0.03 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Actuate Therapeutics Inc.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.05, with a Debt / Equity ratio of 0.
| Current Ratio | 1.05 |
| Quick Ratio | 1.05 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 1344.27 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-2.73M |
| Employee Count | 10 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0.95, so Actuate Therapeutics Inc's price volatility has been higher than the market average.
| Beta | 0.95 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 7.71 |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | 43.95 |
| Average Volume (20 Days) | 31.99K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -25.16M |
| Net Income | -27.29M |
| EBITDA | -25.16M |
| EBIT | -27.3M |
| Earnings Per Share (EPS) | -3.26 |
Balance Sheet
The company has 8.64M in cash and 0 in debt, giving a net cash position of 8.64M.
| Cash & Cash Equivalents | 8.64M |
| Total Debt | 0 |
| Net Cash | 8.64M |
| Retained Earnings | -132.38M |
| Total Assets | 9.32M |
| Working Capital | 405.4K |
Cash Flow
In the last 12 months, operating cash flow was -21.84M and capital expenditures 0, giving a free cash flow of -21.84M.
| Operating Cash Flow | -21.84M |
| Capital Expenditures | 0 |
| Free Cash Flow | -21.84M |
| FCF Per Share | -2.61 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ACTU does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ACTU is $20, which is 180.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $20 |
| Price Target Difference | 180.9% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | -19.95 |
| Piotroski F-Score | 3 |